1 Introduction
This resource has been developed to provide practical information and advice relating to NICE technology appraisal guidance on sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction.
It is intended to be used by both clinical staff and staff that manage and commission heart failure services who are planning to implement the guidance and start using this technology.
NICE's adoption and impact programme worked with NHS clinicians to share their learning and experiences of planning the adoption of this guidance.
The information presented is complementary to the guidance and was not considered by the technology appraisal committee when developing its recommendations.
Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor, including both a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (ARB; valsartan). Both sacubitril and valsartan lower blood pressure.
The learning gained is presented as series of examples of current practice. They are not presented as best practice but as real-life examples of how NHS sites have planned the introduction of this technology.